Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Period	Net Profit Margin
2016-12-31	-2369.00%
2017-12-31	-3296.20%
2018-12-31	-3013.97%
2019-12-31	-2043.34%
2020-12-31	-894.31%
2021-12-31	-15.06%
2022-12-31	-137.95%
2023-12-31	-138.14%
2024-12-31	-303.67%
2025-12-31	-511.90%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCUL	$9.43	-2.18%	6.11M
3
4
5

Ocular Therapeutix Inc. (OCUL) Profit Margin

Profit Margin Data

Get Ocular Therapeutix Inc. Data in Excel

More OCUL Financial Data